Literature DB >> 6797540

Treatment of erythema multiforme secondary to herpes simplex by prophylactic topical acyclovir.

C T Kennedy, I M Leigh, H A Ridgway, M H Wansbrough-Jones, D Brigden.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6797540      PMCID: PMC1507758          DOI: 10.1136/bmj.283.6303.1360

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


× No keyword cloud information.
  4 in total

1.  Controlled clinical trial of intravenous acyclovir in heart-transplant patients with mucocutaneous herpes simplex infections.

Authors:  S Chou; J G Gallagher; T C Merigan
Journal:  Lancet       Date:  1981-06-27       Impact factor: 79.321

2.  Mixed cryoglobulinemia, 125I C1q binding and skin immunofluorescence in erythema multiforme.

Authors:  J C Huff; W L Weston; R I Carr
Journal:  J Invest Dermatol       Date:  1980-05       Impact factor: 8.551

3.  Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients.

Authors:  C D Mitchell; B Bean; S R Gentry; K E Groth; J R Boen; H H Balfour
Journal:  Lancet       Date:  1981-06-27       Impact factor: 79.321

4.  Randomised double-blind trial of acyclovir and idoxuridine in dendritic corneal ulceration.

Authors:  L M Collum; A Benedict-Smith; I B Hillary
Journal:  Br J Ophthalmol       Date:  1980-10       Impact factor: 4.638

  4 in total
  3 in total

1.  Prophylactic topical acyclovir for frequent recurrent herpes simplex infection with and without erythema multiforme.

Authors:  H A Fawcett; M H Wansbrough-Jones; A E Clark; I M Leigh
Journal:  Br Med J (Clin Res Ed)       Date:  1983-09-17

Review 2.  Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-11       Impact factor: 9.546

Review 3.  Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  J J O'Brien; D M Campoli-Richards
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.